论文部分内容阅读
目的:观察去卵巢后大鼠骨组织中核激活因子受体配体、骨保护素蛋白表达和骨密度的动态变化规律。方法:建立去卵巢大鼠模型,于术后2,4,6,8,10周取股骨髁,免疫组化、免疫印记检测骨组织核激活因子受体配体、骨保护素蛋白表达情况,双能X线骨密度仪测量股骨髁的骨密度。结果:大鼠去卵巢6周后股骨髁骨密度开始降低,与对照组相比差异均有统计学意义(P<0.05);免疫组化显示骨髓内细胞核激活因子受体配体染色强度随着去卵巢时间的延长而明显增强,骨保护素染色强度2周时较强,以后逐渐降低;免疫印记显示股骨髁核激活因子受体配体蛋白水平在去卵巢后第6周达到高峰,此后均呈持续高表达,与对照组相比,各时间点表达水平差异有统计学意义(P<0.05);骨保护素蛋白水平在第2周达高峰,此后迅速下降,与对照组相比,各时间点表达水平差异有统计学意义(P<0.05)。结论:去卵巢后大鼠股骨髁是骨密度变化的敏感部位,核激活因子受体配体持续高表达,骨保护素表达短期内升高,迅速降低是绝经后骨质疏松的直接原因。
OBJECTIVE: To observe the dynamic changes of nuclear factor activator receptor ligand, osteoprotegerin and bone mineral density in ovariectomized rats. Methods: Ovariectomized rats were established. The femoral condyles were harvested at 2, 4, 6, 8 and 10 weeks after operation. Immunohistochemistry and Western blotting were used to detect the expressions of nuclear activator receptor ligand and osteoprotegerin, Dual energy X-ray absorptiometry measures femoral condyle bone density. Results: After 6 weeks of ovariectomized, the BMD of the femoral condyle began to decrease in the ovariectomized group compared with that in the control group (P <0.05). Immunohistochemistry revealed that the intensity of the nuclear receptor activating ligand Ovarian prolongation and significantly increased osteoprotegerin staining intensity 2 weeks after the strong, and then gradually reduced; Western blot showed that the femoral condylar nucleus activator receptor ligand protein levels peaked at 6 weeks after ovariectomy, were (P <0.05). Compared with the control group, the expression level of osteoprotegerin peaked at the second week and then decreased rapidly. Compared with the control group, There was significant difference in the expression level at the time point (P <0.05). CONCLUSION: After ovariectomized rats, the femoral condyles are the sensitive sites of bone mineral density changes. The expression of nuclear activator receptor ligands is continuously high. The expression of osteoprotegerin is increased in a short period of time and rapidly decreased. It is the direct cause of postmenopausal osteoporosis.